Skip to main content
Japan's AnGes leads $61M round for biotech startup Emendo
1/17/2020

Emendo Biotherapeutics, a startup that says it develops therapies for diseases that are currently untreatable by using the next generation of CRISPR gene editing technology, raised $61 million in its most recent funding round. Japan-based biopharmaceutical firm AnGes led the Series B round.

Full Story: